Trexquant Investment’s Sutro Biopharma STRO Stock Holding History

Trexquant Investment’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$918K	Sell	27,636 -6,707	-20%	-$209K	0.01%	1489
2026 Q1	$855K	Buy	+34,343	New	+$621K	0.01%	1282
2023 Q4	–	Sell	-2,042	Closed	-$70.9K	–	1767
2023 Q3	$70.9K	Sell	2,042 -8,213	-80%	-$358K	﹤0.01%	1406
2023 Q2	$477K	Sell	10,255 -8,031	-44%	-$400K	0.01%	1024
2023 Q1	$845K	Buy	18,286 +2,865	+19%	+$182K	0.02%	801
2022 Q4	$1.25M	Buy	15,421 +9,634	+166%	+$670K	0.04%	566
2022 Q3	$321K	Buy	+5,787	New	+$343K	0.01%	998
2022 Q1	–	Sell	-1,404	Closed	-$209K	–	1712
2021 Q4	$209K	Buy	+1,404	New	+$252K	0.01%	1125
2020 Q3	–	Sell	-3,260	Closed	-$253K	–	1519
2020 Q2	$253K	Buy	+3,260	New	+$313K	0.02%	963
2020 Q1	–	Sell	-1,022	Closed	-$112K	–	1402
2019 Q4	$112K	Buy	+1,022	New	+$105K	0.01%	974

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Trexquant Investment's STRO Position: Q2 2026 in Review

Trexquant Investment reduced its Sutro Biopharma (STRO) stake by 20% in Q2 2026, selling an estimated $209K and leaving 27,636 shares worth $918K. The position accounts for 0.01% of the portfolio, ranked #1489.

Trexquant Investment first reported a position in STRO in Q4 2019 and has held it in 10 quarters since. The position peaked at $1.25M in Q4 2022. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Trexquant Investment held 27,636 shares of Sutro Biopharma worth $918K as of Q2 2026.
Trexquant Investment sold 6,707 Sutro Biopharma shares in Q2 2026, an estimated $209K.
Sutro Biopharma made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1489 holding.
Trexquant Investment first reported a position in Sutro Biopharma in Q4 2019 and has held it in 10 quarters since.
Trexquant Investment's Sutro Biopharma position peaked at $1.25M in Q4 2022.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.